HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herrero, P. Articles by Gropler, R. J. Search for Related Content PubMed PubMed Citation Articles by Herrero, P. Articles by Gropler, R. J.

L-3-¹¹C-Lactate as a PET Tracer of Myocardial Lactate Metabolism: A Feasibility Study

Division of Radiological Sciences, Edward Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri

Correspondence: For correspondence contact: Pilar Herrero, ME, MS, Cardiovascular Imaging Laboratory, Edward Mallinckrodt Institute of Radiology, 510 S. Kingshighway Blvd., St. Louis, Missouri 63110. E-mail: herrerop{at}mir.wustl.edu

Lactate is a key myocardial energy source. Lactate metabolism is altered in a variety of conditions, such as exercise and diabetes mellitus. However, to our knowledge, noninvasive quantitative measurements of myocardial lactate metabolism have never been performed because of the lack of an adequate radiotracer. In this study we tested L-3-¹¹C-lactate (¹¹C-lactate) as such a tracer. Methods: Twenty-three dogs were studied under a wide range of metabolic interventions. ¹¹C-Lactate and ¹³C-lactate were injected as boluses and PET data were acquired for 1 h. Concomitant arterial and coronary sinus (ART/CS) blood samples were collected to identify ¹³C-lactate metabolites and to measure fractional myocardial extraction/production of ¹¹C metabolite fractions (¹¹C acidic: ¹¹CO₂ and ¹¹C-lactate; ¹¹C basic: ¹¹C-labeled amino acids; and ¹¹C neutral: ¹¹C-glucose). Lactate metabolism was quantified using 2 PET approaches: monoexponential clearance analysis (oxidation only) and kinetic modeling of PET ¹¹C-myocardial curves. Results: Arterial ¹¹C acidic, neutral, and basic metabolites were identified as primarily ¹¹C-labeled lactate + pyruvate, glucose, and alanine, respectively. Despite a significant contribution of ¹¹C-glucose (23%–45%) and ¹¹C-alanine (<11%) to total arterial ¹¹C activity, both were minimally extracted(+)/produced(–) by the heart (1.7% ± 1.0% and –0.12% ± 0.84%, respectively). Whereas extraction of ¹¹C-lactate correlated nonlinearly with that of unlabeled lactate extraction (r = 0.86, P < 0.0001), ¹¹CO₂ production correlated linearly with extraction of unlabeled lactate (r = 0.89, P < 0.0001, slope = 1.20 ± 0.13). In studies with physiologic free fatty acids (FFA) (415 ± 216 nmol/mL), ¹¹C-lactate was highly extracted (32% ± 12%) and oxidized (26% ± 14%), and PET monoexponential clearance and kinetic modeling analyses resulted in accurate estimates of lactate oxidation and metabolism. In contrast, supraphysiologic levels of plasma FFA (4,111 ± 1,709 nmol/mL) led to poor PET estimates of lactate metabolism due to negligible lactate oxidation (1% ± 2%) and complete backdiffusion of unmetabolized ¹¹C-lactate into the vasculature (28% ± 22%). Conclusion: Under conditions of net lactate extraction, L-3-¹¹C-lactate faithfully traces myocardial metabolism of exogenous lactate. Furthermore, in physiologic substrate environments, noninvasive measurements of lactate metabolism are feasible with PET using myocardial clearance analysis (oxidation) or compartmental modeling. Thus, L-3-¹¹C-lactate should prove quite useful in widening our understanding of the role that lactate oxidation plays in the heart and other tissues and organs.

Key Words: myocardial lactate oxidation • L-3-¹¹C-lactate • PET • kinetic modeling

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11A-12A. [Full Text]  

This article has been cited by other articles:

				R. W. van der Meer, L. J. Rijzewijk, H. W.A.M. de Jong, H. J. Lamb, M. Lubberink, J. A. Romijn, J. J. Bax, A. de Roos, O. Kamp, W. J. Paulus, et al. Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus Circulation, April 21, 2009; 119(15): 2069 - 2077. [Abstract] [Full Text] [PDF]

				A. J. Sinusas, F. Bengel, M. Nahrendorf, F. H. Epstein, J. C. Wu, F. S. Villanueva, Z. A. Fayad, and R. J. Gropler Multimodality Cardiovascular Molecular Imaging, Part I Circ Cardiovasc Imaging, November 1, 2008; 1(3): 244 - 256. [Full Text] [PDF]